(NASDAQ: BCTX) Briacell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.45%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.3%.
Briacell Therapeutics's earnings in 2025 is -$19,621,152.On average, 1 Wall Street analyst forecast BCTX's earnings for 2026 to be -$11,993,683, with the lowest BCTX earnings forecast at -$11,993,683, and the highest BCTX earnings forecast at -$11,993,683. On average, 1 Wall Street analyst forecast BCTX's earnings for 2027 to be -$9,757,572, with the lowest BCTX earnings forecast at -$9,757,572, and the highest BCTX earnings forecast at -$9,757,572.
In 2028, BCTX is forecast to generate -$5,759,678 in earnings, with the lowest earnings forecast at -$5,759,678 and the highest earnings forecast at -$5,759,678.